$PODDBullishLow

WEATHERMAN ELIZABETH H purchased $497K of PODD

WEATHERMAN ELIZABETH H purchased 3,450 shares of INSULET CORP (PODD) at $144.20 ($0.50M total) on 2026-06-03.

6/10
8/10
Low
Bullish
today’s SEC Form 4 disclosure (2026-06-03)
mildly positive (insider buying)

An SEC Form 4 insider open-market buy signals confidence but is not a fundamental catalyst by itself.

Insider director Elizabeth H. Weather-man purchased 3,450 shares of Insulet (PODD) on 2026-06-03 at $144.20/share via open-market transaction.

Likely limited near-term impact; any effect is typically small and short-lived unless part of a broader pattern.

Background

The article is an SEC Form 4 insider transaction disclosure for Insulet’s director.

Why it matters

Traders may treat it as a sentiment input, but without accompanying earnings/guidance/contract updates it usually won’t drive a durable repricing.

Market relevance

A disclosed director open-market buy can slightly support sentiment, but it lacks fundamental new information.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide driver.

None indicated.

None indicated.

Alternative perspectives

Insider buys can be routine (liquidity needs, diversification, or non-informational timing) and may not reflect near-term fundamentals.

No 10b5-1 plan is cited, but the article also doesn’t indicate whether this is part of a series of buys/sells or driven by pre-existing compensation/option exercises.

Key entities

  • Insulet Corp

    Subject of the SEC Form 4 insider purchase; director bought 3,450 shares at $144.20/share.

  • WEATHERMAN ELIZABETH H

    Director who executed the open-market purchase disclosed on 2026-06-03.

Related articles

$PODDLow

3 Reasons We’re Fans of Insulet (PODD)

The article says Insulet (NASDAQ:PODD) has seen its shares fall 54.4% over the past six months to $144.10. It highlights three factors: constant-currency revenue averaging 26.8% year-on-year growth over two years, a rise in free-cash-flow margin to 13.6% over the trailing 12 months, and higher ROIC. It also notes the stock trades at 21.3× forward P/E.

$PODDMedAI 8/10

William Blair Initiates on Insulet (PODD) With Outperform and Says the Valuation Gap Is Hard to Justify

William Blair analyst Steve Lichtman initiated coverage of Insulet (PODD) with an Outperform rating on May 20, citing a valuation gap versus peers and a stronger revenue trajectory after the stock’s selloff. He warned competition from device makers in pharmacy distribution and the tubeless pump market, plus uncertainty about capturing type 2 diabetes patients as GLP-1 drugs grow. Catalysts include US salesforce expansion, product pipeline, and international growth.

$ZSHighAI 9/10

Stocks making the biggest moves premarket: Micron, ZScaler, MGM, Bath & Body Works and more

Premarket movers: Zscaler shares fell over 23% after guiding current-quarter revenue to $875M–$878M vs $879M expected, despite fiscal Q3 adjusted EPS of $1.08 beating $1.01 and revenue of $850M beating $835M. Bath & Body Works rose 15% on better guidance; Semtech gained 7% on beats and upside outlook. Micron rose 7% after topping $1T market cap; Sandisk up 3% on Barclays upgrade.

$PODDMedAI 8/10

Stock futures are little changed after the S&P 500 closes at another record: Live updates

U.S. stock futures were little changed Tuesday night after tech shares pushed the S&P 500 and Nasdaq to record closes. S&P 500 futures and Nasdaq 100 futures were about 0.1% lower; Dow futures were down ~17 points. Zscaler fell 19% on weaker-than-LSEG-expected current-quarter revenue guidance, while Insulet dropped 8% after a voluntary device correction. The S&P 500 rose 0.61% and Nasdaq 1.19% in the regular session; Dow fell 0.23%. Citi strategist Drew Pettit said higher yields and inflation ex

$BOXHighAI 9/10

Stocks making the biggest moves after hours: Zscaler, Insulet, Box and more

After-hours movers: Box fell 2% after full-year adjusted EPS guidance of $1.56 vs $1.63 expected, though Q1 adjusted EPS was 37 cents on $306M revenue vs 36 cents and $304M. Zscaler dropped 16% on current-quarter revenue guidance of $875–$878M vs $879M, despite fiscal Q3 EPS of $1.08 and $850M revenue. Semtech rose 8% on Q1 and upbeat guidance; Insulet fell ~9% on a voluntary pod correction tied to insulin under-delivery risk.